Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028. This funding supports the advancement of multiple clinical trials for its CAR-T therapy Descartes-08 targeting autoimmune diseases like myasthenia gravis and myositis. Key clinical data readouts are expected in the first half of 2027, including Phase 3 AURORA trial topline data for myasthenia gravis in Q1 2027 and subsequent BLA filing planned for mid-2027. The financing also accelerates pre-launch activities, positioning Cartesian for potential commercial launch of Descartes-08.
Berkshire Hathaway is well-positioned to benefit from rising interest rates, holding $324.9 billion in Treasury bills that will reprice higher, alongside a $177.5 billion insurance float that funds its growth. Despite concerns about succession, Greg ...
GH Research PLC has resolved the FDA clinical hold on its investigational new drug (IND) application for GH001, a treatment targeting resistant depression. This clearance allows the company to plan a pivotal phase 3 trial expected to begin in 2026. G...
The Congressional Black Caucus (CBC) is strongly supporting legislation to regulate artificial intelligence, with nearly all of its 62 members ready to vote in favor of AI guardrails to ensure transparency and safety. CBC leaders emphasize the need t...
The US State Department has urged Americans outside the Middle East to reconsider travel due to the risk of rapid escalation in the Iran conflict. Iran insists the Strait of Hormuz will remain closed until its demands are met, including ending the na...
Toyosa, a Toyota dealer in Bolivia, has introduced Bitcoin as a payment option for purchasing Toyota vehicles, adding to its existing payment methods including bolivianos, U.S. dollars, and USDT stablecoins. This expansion follows Bolivia's 2024 regu...
